Natalie Baratta is a board-certified Adult Gerontology Nurse Practitioner currently specializing in genetics and personalized cancer prevention. She graduated with a master's in nursing from Hunter College in 2022 and prior to that spent 8 years working as an RN in medical-surgical, ICU, and perioperative services. She is dedicated to helping assess cancer risk in her patients and assist with tailored screening programs and care coordination.

Dr. Innocent Clement is a physician, entrepreneur, and innovator focused on transforming how chronic disease is prevented and treated. He is the founder and CEO of Ciba Health, a precision care platform helping patients prevent and reverse complex chronic conditions through advanced diagnostics, physician-led care teams, and a root-cause approach.

Previously, he was the co-founder and CEO of Kaia Health, a digital therapeutics company using AI and computer vision to deliver evidence-based treatments for chronic conditions, where he led the company’s expansion in the United States.

Dr. Clement serves on the board of the CUNY Graduate School of Public Health and Health Policy and is passionate about leveraging technology, science, and innovation to improve health outcomes and build the future of healthcare.

Olivier Elemento, PhD, is the Director at the Englander Institute for Precision Medicine at Weill Cornell Medicine, a large multi-disciplinary institute that uses precision medicine technologies and informatics to uncover the molecular mechanisms of disease and individualize disease treatment and prevention. In addition, he is a full Professor of Systems and Computational Biomedicine, Associate Director of the Institute for Computational Biomedicine at Weill Cornell Medical College, and Associate Director of the Clinical and Translational Science Center at Weill Cornell Medical College. Dr. Elemento’s research group combines Big Data, Artificial Intelligence with experimentation and genomic profiling to accelerate the discovery of cancer cures. Dr. Elemento and his team have published over 500 scientific papers in the area of precision medicine, genomics, epigenomics, artificial intelligence, computational biology and drug discovery. He is a recipient of awards including the NSF CAREER Award, Siegel Family Award for Outstanding Medical Research, the Irma T. Hirschl Career Scientist Award and the Daedalus Fund for Innovation Award. His research group has developed new assays and analytical pipelines for cancer genome and epigenome analysis, clinical sequencing and precision medicine. They led the development of the first New York State approved whole exome sequencing test for oncology and pioneered new methods for assessing tumor-driving pathways, the immune landscape of tumors and predicting immunotherapy responders. In addition, Dr. Elemento and his lab developed methodologies to repurpose existing drugs to target specific pathways, predict drug toxicity and identify synergistic drug combinations. His research has been highlighted in broad audience media outlets, including the New York Times Magazine, NPR, Wired, Popular Science, CBS, Gizmodo, and Huffington Post.

Zahi A. Fayad, PhD, is the Lucy G. Moses Professor of Medical Imaging and Bioengineering at the Icahn School of Medicine at Mount Sinai, where he also serves as Vice Chair for Research in Radiology and holds professorships in Medicine (Cardiology) and AI & Human Health. He is the founding Director of the BioMedical Engineering and Imaging Institute (BMEII), home to one of the nation’s top NIH-funded radiology programs (#2 in 2024 per Blue Ridge rankings). Dr. Fayad also co-leads the Mount Sinai system-wide Healthspan initiative, coordinating research, clinical, and digital infrastructure to advance precision prevention across the enterprise.

Dr. Fayad is Principal Investigator on multiple major grants, including five NIH-funded projects (3 R01s, 2 P01s) supported by the National Heart, Lung, and Blood Institute, NIAID, and NIDA. A leader in biomedical engineering, his interdisciplinary work integrates advanced imaging, AI, and nanomedicine to drive precision medicine, particularly in cardiovascular disease.

He is a Clarivate Highly Cited Researcher (since 2018) with over ~190,000 citations and an h-index of 142. His seminal contributions include MRI vessel wall imaging (leading to CARADS), FDG PET imaging of vascular inflammation, and defining the link between amygdala activity, systemic inflammation, and cardiovascular risk. His research on HDL-based nanoparticles for immune modulation is progressing toward clinical translation for cancer, autoimmune diseases, and transplant rejection.

Dr. Fayad’s current projects span cardiovascular, neuroimmune, and transplant-focused research, including stress-induced immune dysregulation; mitral valve prolapse and arrhythmia risk; cocaine use–related carotid atherosclerosis and cognitive impairment; cardiac sarcoidosis therapy monitoring; and immune tracking in organ rejection using nanobiologics.

He also leads the Mount Sinai DigiTwin Project, an AI-driven platform designed to personalize health optimization by integrating imaging, real-time physiologic data, and advanced analytics—initially focused on cardiovascular health and now expanding to whole-person healthspan modeling. Dr. Fayad and colleagues at Mount Sinai are finalists in the XPRIZE Healthspan competition, where they are evaluating a multimodal strategy to meaningfully extend human healthspan.

Hortense Gimonet-Lee is a data scientist who spent six years thinking about improving clinical care through software at 91Life, a health tech startup specializing in remote monitoring of cardiac implantable electronic devices. She joined as a data scientist focused on data migration and onboarding, working closely with clinical staff to get the platform running at hospitals. She then moved into leading R&D, collaborating with physicians to build labeling pipelines and machine learning models for clinical research and product development, guided by the principle that carefully curated datasets and intentional labeling produce better models for arrhythmia detection. She holds a BA in Mathematics from Cornell University and an MS in Machine Learning from Cornell Tech. She recently founded Amicus, a litigation productivity platform where she aims to bring her expertise in human-centered delivery of traceable AI models.

Dr. Amir H. Goldan is an Associate Professor of Radiology at Weill Cornell Medicine. His research focuses on developing noninvasive virtual imaging technologies for routine monitoring of brain health and for the early screening of brain disorders, including Alzheimer’s and Parkinson’s disease. Dr. Goldan’s work has been supported by the National Institute of Biomedical Imaging and Bioengineering and the National Institute on Aging at the NIH. The overarching mission of Dr. Goldan’s research is to enable earliest detection of brain disorders, years before clinical symptoms emerge, at a stage when non-invasive intervention can promote brain resilience and self-healing.

Julia Iyasere, MD, MBA is Senior Vice President and System Chief Medical Officer at NewYork-Presbyterian and Executive Director of the Dalio Center for Health Justice. In this role, she leads the Center's efforts to address longstanding health disparities due to race, socio-economic differences, limited access to care, and other complex factors that impact the wellbeing of our communities disproportionately. Established in 2020, the Center for Health Justice works collaboratively with representatives from NewYork-Presbyterian, Weill Cornell Medicine, and Columbia Vagelos College of Physicians and Surgeons to be a leader in the understanding and improving of health equity, and to drive action that results in measurable improvements in health outcomes for all. Dr. Iyasere brings more than a decade of experience in medicine to her role. She was previously the Associate Chief Medical Officer for Service Lines and the Co-Director of the Care Team Office. She was also Director of the Leadership Education and Development for Physicians (LEAD) Academy, Associate Designated Institutional Official for Graduate Medical Education at NYPH, and the Associate Program Director of the Columbia Internal Medicine Residency Training Program. An Assistant Professor of Clinical Medicine at Columbia University Irving Medical Center, Dr. Iyasere continues to see patients as an internist in the Section for Hospital Medicine.

Dr. Andres Jimenez is a physician entrepreneur, healthcare innovator, and Founder & CEO of HealthPrevent360, a company focused on transforming prevention through AI, emerging technologies, and more personalized models of care. Board-certified in Public Health and General Preventive Medicine and Clinical Informatics, Dr. Jimenez works at the intersection of medicine, data, and innovation to help move healthcare upstream—toward earlier risk detection, more precise prevention, and smarter patient engagement. His work is centered on reimagining how prevention is delivered, using technology to close care gaps, personalize decision-making, and build scalable solutions that better align patients, clinicians, and health systems. As both a physician and founder, he brings a practical and visionary perspective on how AI can help shape the next generation of patient-centered preventive care.

Rohan Jotwani, MD, MBA, is an academic anesthesiologist and pain medicine specialist at Weill Cornell Medicine, and practices clinically in both fields. He also serves as the Editor-in-Chief of the Journal of Medical Extended Reality. In his roles as the Nanette Laitman Scholar in XR/AI and the Co-Director of the Extended Reality Anesthesiology Immersion Lab, he advances the use of extended reality to enhance medical training and patient care.

Dr. Jotwani completed his anesthesiology residency at NewYork-Presbyterian/Weill Cornell, Hospital for Special Surgery, and Memorial Sloan Kettering Cancer Center. He further specialized with a Pain Medicine fellowship at Harvard’s Brigham and Women’s Hospital. His clinical practice focuses on advanced forms of interventional and multidisciplinary pain management for patients living with acute and chronic pain conditions.

His research focuses on the intersection of pain management and technology, particularly exploring virtual reality applications for chronic pain treatment and medical education. Dr. Jotwani research has been funded by Bodyswaps/Meta, the ACGME, and the Nanette Laitman foundation. His expertise has been featured in major news outlets such as The Boston Globe and The New York Times, and he has published extensively in peer-reviewed journals.

Craig Kenesky, Ph.D., is a partner in Brown Rudnick’s Global Life Sciences Group and Emerging Growth Companies & Venture Capital Group. Craig advises technology companies, emerging ventures, and venture capital investors on IP strategy and the development, protection, and commercialization of patent portfolios across a broad range of technologies.  Craig is actively engaged in the life sciences and startup communities through speaking engagements and mentorship, regularly advising founders and investors at the intersection of science, law, and commercialization.

Spencer Kimber is an Investment Principal at Shannon Life Sciences, where he leads the private capital investment strategy across biopharma venture capital, healthcare services, and CPG. With 12+ years of experience spanning private equity, venture capital, corporate development, and strategy consulting, Spencer has led or advised on over $5B in transactions including acquisitions, investments, and strategic partnerships across the healthcare and life sciences ecosystem. Prior to Shannon, he served as Associate Principal at IQVIA advising PE and VC firms on healthcare investments, and as Director of Strategy and Corporate Development at Oracle Cerner, where he led M&A and corporate venture capital initiatives. Spencer has built LLM-powered research infrastructure to automate deal screening, pipeline analysis, and competitive intelligence -- bridging his investment expertise with emerging AI capabilities. He holds an MBA from Cornell University, an MS from Johns Hopkins University (Regulatory Science/Biotechnology), and a BA from UNC Wilmington (Economics & Chemistry).

Jennifer Kindman, M.D. is an Assistant Professor of Emergency Medicine in Clinical Radiology and Assistant Professor of Clinical Emergency Medicine at Weill Cornell Medicine, and an Assistant Attending Physician at the NewYork-Presbyterian Hospital. Dr. Kindman graduated from Duke University, where she earned her B.A. She worked in finance briefly before returning to school to pursue her dream of being a doctor. She completed the Premedical Postbaccalaureate program at Columbia University and went on to earn her M.D. at Columbia University. She completed residency training in Emergency Medicine at NewYork-Presbyterian Brooklyn Methodist Hospital and is Board Certified in Emergency Physician by the American Board of Emergency Medicine (ABEM). Prior to joining the GPCP faculty at Weill Cornell in 2024 she practiced Emergency Medicine at Middlesex Hospital in Connecticut and at Sollis Health in New York City. In addition to her role in GPCP, she continues to work clinically in the Emergency Department. In her free time, she enjoys working out, birding, and simply being outdoors in nature.

Physician. Surgeon. MBA-trained executive. With more than 20 years in healthcare spanning clinical practice, digital health, and enterprise technology, I advise the organizations trying to get transformation right.

I trained as a physician and surgeon: the kind of clinical foundation that grounds everything else I do. Medicine taught me how to think under pressure, how to make high-stakes decisions with incomplete information, and what it means to be accountable when a decision goes wrong.

Before Oracle, I built operating experience inside digital health and health technology startups, holding VP and C-suite roles across multiple early-stage and growth-stage companies. That included one exit to private equity: the experience of building something, scaling it, and watching an institutional buyer put a number on what the team had built. It changes how you think about strategy.

Then I moved into enterprise health technology. I led product strategy for Oracle Health's clinical AI and digital transformation portfolio, one of the largest health IT platforms in the world. That experience put me in the rooms where policy gets written, technology gets sold, and care models get designed at scale.

I watched most of them fail at the implementation layer.

Not because the technology was wrong. Not because the strategy was bad. But because the people designing the systems had never actually practiced medicine; and the people practicing medicine had no seat at the table when the systems were designed.

I bridge that gap. That is the through-line of a 20-year career in healthcare, and it's the entire premise of The Borderless Healthcare Revolution.

Now I advise health systems navigating AI adoption, payers redesigning care models, digital health companies trying to understand why their product doesn't stick inside a hospital, and investors who need someone who can tell the difference between a real use case and a compelling demo.

Isaac Michaels, DrPH, MPH, is a public health professional and epidemiologist whose work focuses on connecting research with practice to improve community health and health systems performance. He serves as a Senior Data Scientist at NewYork-Presbyterian, where he applies analytics and research methods to initiatives spanning community health, health equity, quality and patient safety, and healthcare operations. His career has included roles in government and hospital settings, providing a broad perspective on public health practice and health policy. Dr. Michaels holds a DrPH in Epidemiology and an MPH from the University at Albany, and a BA in Mathematics and Anthropology from Binghamton University.

Joseph E. Safdieh, MD is the Richard P. Cohen MD Senior Associate Dean for Education, Vice Chair for Education and Professor of Neurology at Weill Cornell Medicine. A neurologist and nationally recognized educator, he oversees the MD, CME and PA programs and has developed numerous curricula for teaching neurology to medical students and residents. He previously directed the neurology clerkship and outpatient residency training at Weill Cornell. Dr. Safdieh is editor-in-chief of Neurology Today, vice chair of the AAN publications committee, and former chair of the Consortium of Neurology Clerkship Directors. He completed neurology residency and chief residency at Weill Cornell after earning his MD from NYU.

Yiye Zhang PhD is Associate professor in Population Health Sciences and Emergency Medicine at WCM, Informatics Director of Clinical Decision Support at NYPH, and Founding Editor in Chief at Nature portfolio Journal (NPJ) Health Systems. Her expertise lies in the development, translation, and evaluation of AI-enabled clinical decision support tools to real-world patient care. Dr. Zhang’s research has been funded by NIH and AHRQ, and her research has previously been commercialized with WCM Bioventure. She holds a PhD in Information Systems Management from Carnegie Mellon University and a MS in Biostatistics from Columbia University.